We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants to See More Stability Data for Clearside’s Macular Edema Drug
FDA Wants to See More Stability Data for Clearside’s Macular Edema Drug
Clearside Biomedical received a complete response letter (CRL) from the FDA for its macular edema drug candidate over the need for additional stability data.